Announcements Trials
Browse Landscape

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 14Observational 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 13Neoplasms 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Sarcopenia 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Neoplasms, Squamous Cell 1Motor Activity 1Lung Squamous Cell Carcinoma Stage IV 1Locally Advanced Melanoma 1Locally Advanced Gastric Cancer 1Liver Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Eunuchism 1Esophageal Neoplasms 1Erectile Dysfunction 1

Interventions

Drug Therapy 4Positron Emission Tomography Computed Tomography 2Nivolumab 2Magnetic Resonance Imaging 2Immunohistochemistry 2Diffusion Magnetic Resonance Imaging 2Blood Specimen Collection 2Biopsy 2Tomography, X-Ray Computed 1Surgical Procedures, Operative 1Radiotherapy 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1Mass Spectrometry 1Lymph Node Excision 1In Situ Hybridization, Fluorescence 1Immunotherapy 1Immune Checkpoint Inhibitors 1Gastroscopy 1Fluorouracil 1Esophagectomy 1Endoscopy 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Cisplatin 1Base Sequence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Esophageal Squamous Cell Carcinoma × Nivolumab × Clear all
NCT06504615 2026-04-03

METAGIO

Bristol-Myers Squibb

Active not recruiting
208 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma

NCT04936399 2022-05-25

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Bristol-Myers Squibb

Completed
87 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡